## Amendments to the Specification:

Please replace Table 2 on page 27, lines 11-18, with the following:

## [TABLE 2]

		Αβx-40	Αβx-42
· · · · · · · · · · · · · · · · · · ·		(pmol/g wet tissue)	(pmol/g wet tissue)
Plasma (intact)			
	IgG Group	$3160 \pm 302$ $3.16 \pm 0.302$	$389 \pm 20.0 \ 0.389 \pm 0.02$
	BC-05a Group	$\frac{2270 \pm 186}{2.27 \pm 0.186}$	$8810 \pm 224 \ 8.81 \pm 0.224$
Plasma (treated with	guanidine)		
	IgG Group	$\frac{2990 \pm 208}{2.99 \pm 0.208}$	$588 \pm 29.0 \ 0.588 \pm 0.029$
	BC-05a Group	$\frac{2350 \pm 128}{2.35 \pm 0.128}$	$18800 \pm 1100 \ 18.8 \pm 1.10$
Brain soluble Aβ	-		
·	IgG Group	$2.23 \pm 0.402$	$0.413 \pm 0.0521$
*	BC-05a Group	$2.29 \pm 0.27$	$0.643 \pm 0.0687$
Brain insoluble Aβ	•		
•	IgG Group	$1650 \pm 383$	$645 \pm 102$
	BC-05a Group	$1200 \pm 347$	$442 \pm 57.4$
mean + S F M			